Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
3.760
-0.060 (-1.57%)
Nov 9, 2026, 9:42 AM EST - Market open

Vanda Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
229.28216.11198.77192.64254.38268.68
Revenue Growth
8.11%8.72%3.18%-24.27%-5.32%8.27%
Gross Profit
214.57203.06187.46177.84230.1243.05
Operating Income
-177.91-151.17-40.66-13.956.3342.17
Net Income
-274.83-220.47-18.92.516.2833.15
Earnings Per Share
-4.59-3.74-0.330.040.110.58
EPS Growth
----63.64%-81.03%38.09%

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
140.49263.85374.64388.26466.86432.81
Total Debt
21.9712.6212.369.411.1412.37
Net Cash (Debt)
118.52251.23362.28378.86455.72420.45
Net Cash Growth
-58.09%-30.65%-4.38%-16.86%8.39%18.73%
Net Cash Per Share
1.984.266.236.588.007.39

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-139.14-109.44-15.7612.831.9864.21
Capital Expenditures
-0.82-1-4.72-101.05-0.68-0.55
Free Cash Flow
-139.96-110.44-20.48-88.2531.3163.66
Free Cash Flow Growth
-----50.83%27.38%

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
93.59%93.96%94.31%92.32%90.45%90.46%
Operating Margin
-77.59%-69.95%-20.46%-7.24%2.49%15.69%
Pretax Margin
-74.67%-64.16%-11.53%3.29%4.44%15.77%
Profit Margin
-119.87%-102.02%-9.51%1.30%2.47%12.34%
FCF Margin
-61.05%-51.11%-10.30%-45.81%12.31%23.69%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
---96.7766.6526.37
Forward PE
-23.7423.7423.7421.7421.94
P/FCF Ratio
----13.3613.73
PS Ratio
1.012.411.411.261.643.25